Efkarpia

• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• The WILLOW LTE study with enpatoran in participants with SCLE, DLE and/or SLE Ended recruitment
  2024-510871-39-00 4 2022-11-21 Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (
• Endoscopic evidence of maintenance of healing with oral NEXIUM in patients 1 to 11 years old with erosive esophagitis. Ended recruitment
  2023-505454-18-00 5 2021-11-24 Erosive Esophagitis
• EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER … Ended recruitment
  2023-506786-63-00 5 2021-09-30 Breast Cancer
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma … Ended recruitment
  2022-502937-24-00 5 2019-01-02 Atopic Dermatitis
• Open-label basket study for safety and pharmacokinetics evaluation of INF904 in subjects with CSU or HS Ended
  2024-515615-22-00 4 2025-04-02 Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to
• A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended
  2023-508337-14-00 4 2025-03-18 Myositis, Dermatomyositis
• Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with … Ended
  2024-514562-40-00 4 2025-03-13 Hidradenitis suppurativa (HS)
• A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended
  2024-515959-38-00 4 2025-03-06 Hidradenitis Suppurativa
• Multicenter, Prospective, Open-label, Randomized, Crossover Study to Evaluate Pharmacokinetics (PK), Safety, and Tolerability of TAK-881 in … Ended
  2022-502095-23-01 10 2024-09-10 Primary Immunodeficiency Diseases
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment … Ended
  2023-509738-20-00 6 2024-07-11 Plaque Psoriasis
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa … Ended
  2023-508377-82-00 10 2024-06-27 Hidradenitis Suppurativa (HS)
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended
  2022-501196-41-00 5 2024-05-29 Dermatitis atopic
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject … Ended
  2023-505842-24-00 5 2024-05-07 Moderate to Severe Plaque Psoriasis
• A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Ended
  2022-501890-38-00 4 2024-02-16 acute ischemic stroke
• Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended
  2023-504346-66-00 4 2024-02-14 Dermatitis atopic
• A Phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidrade … Ended
  2023-504328-25-00 4 2023-12-27 hidradenitis suppurativa
• A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended
  2023-503315-15-00 4 2023-12-20 Thrombolysis of symptomatic proximal vein thrombosis
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight … Ended
  2022-502678-18-00 5 2023-11-07 Type 2 diabetes
• A study to test whether spesolimab helps people with a skin disease called hidradenitis suppurativa Ended
  2022-501074-19-00 10 2023-10-13 Hidradenitis suppurativa
• A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) Ended
  2022-502837-24-00 5 2023-09-25 Overweight
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa

Showing 73–96 of 114 trials